Chapter 5: Gene Therapy & Pharmacogenomics

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to The Deep Dive, where we extract the cutting edge insights you need, leaving the information overload behind.

Today we are diving deep into the science that is fundamentally changing how we approach medication.

We're talking about a complete shift, really, moving away from one -dose -fits -all towards therapy driven entirely by your personal genetic blueprint.

The mission for this deep dive is pretty straightforward.

To map out the landscape of gene therapy and pharmacogenomics.

Think of this as your essential shortcut.

We'll cover the basic building blocks, the breakthrough clinical applications, and, crucially, why recognizing genetic variation is becoming, well, maybe the most important skill in future healthcare practice.

Absolutely.

What's so fascinating here is we're learning not just what a drug does in the body, that's traditional pharmacology, we're now integrating genomics, the study of the entire human code, to understand why you, as an individual, respond uniquely to the exact same medication someone else might take.

If we connect this to the bigger picture, we are realizing that genetics informs every single step of future drug dosing.

It's foundational.

And that's the ultimate goal, right?

Personalized medicine.

But okay, to really get there, we have to start at the source of all this variation.

When we talk about heredity, the chapter mentions the code itself, the genotype, and then how that code gets expressed in the body that's the phenotype.

So where does the variation that actually affects drug response come from?

Where does it start?

Well, it really begins with alleles.

Remember, you get two alternative forms of every gene, one from each parent.

The specific combination of those alleles, that's what determines your gerotype.

And if we zoom out a bit, we see that this genetic con can determine if a disease is an inherited disease, meaning defective alleles passed down through generations, or a broader genetic disease, which could include spontaneous anomalies too, not just inherited ones.

Okay, so there are different categories.

Right.

But the really relevant point for pharmacotherapy, for drug action, is this concept of genetic predisposition.

This is where your genome just increases the likelihood, the chance, of developing a condition, say, like atherosclerotic heart disease.

It's often something that can be mitigated by lifestyle, by environment.

It's not a guarantee, just a predisposition.

But the key takeaway is the code you inherit doesn't just influence disease risk.

It fundamentally dictates how well you process every single substance that enters your body, including medications.

And all of this incredibly complex programming relies on that fundamental process, protein synthesis.

It sounds basic, but it's everything.

The whole genetic system exists just to turn that DNA code into proteins.

And proteins are the biochemical workhorses running the body.

Can you give us the quick rundown of how that happens?

Because any hiccup there, that's where mutations and therefore different drug responses can happen?

Sure.

It's basically a two -step dance.

First you have transcription, the DNA double helix unwinds, and a messenger molecule, mRNA, is formed, copying the code.

Okay, step one.

Copy the code.

Exactly.

Step two is translation.

That mRNA molecule travels out of the nucleus to the ribosomes, think of them as protein factories, and there the mRNA is read using three base codes like instructions.

Then another type of RNA, transfer RNA or tRNA, brings in the correct amino acids, one by one linking them together to form the protein chain.

The crucial insight here is that even a tiny change, a single mutation in that original DNA sequence, can completely alter the final protein's shape.

And if you change the shape, you often destroy its function.

That has profound impacts on how drugs work or don't work.

So once scientists really grasped those tiny details, the code itself, they immediately started thinking bigger, scaling up.

Which brings us to the genomic revolution, the genome that's the complete set of all your genetic material, right?

And genomics is the study of that structure and function in health and disease.

And that scaling up really culminated in the Human Genome Project.

That massive worldwide effort ran from 1990 to 2003.

That's right, a huge international collaboration.

Its main goal wasn't just mapping the three billion base pairs, though, was it?

It was really about laying the groundwork for, well, for better prevention,

treatment, cures for pretty much every disease.

Exactly, setting the stage for the future.

And that mapping effort has now scaled even further into proteomics, the detailed study of the proteome, which is the entire set of proteins our genes actually produce.

It's the next layer.

OK, so the HGP laid the foundation.

Yes, and that groundwork made gene therapy a tangible possibility.

The chapter defines this as an experimental technique.

It uses genes themselves, not traditional drugs or surgery, to treat or prevent disease.

Essentially, researchers are trying to go in and fix the broken code directly.

How do they do that?

What are the approaches?

Well, there are three main strategies being researched.

One is replacing a mutated gene with a healthy copy.

Another is introducing a completely new gene to help fight a disease.

Or sometimes the goal is just to inactivate a gene that's malfunctioning and causing problems.

OK, let's clarify the two main forms of gene therapy, because I think this often confuses people.

First, there's direct gene therapy.

This involves actually delivering artificially produced DNA splices.

The chapter calls this recombinant DNA or rDNA straight into the patient cells.

But you can't just inject raw DNA, right?

It needs a delivery system.

Exactly.

You need a vehicle, something to carry the gene into the target cells.

That vehicle is called a vector.

And what are they using for vectors?

The most common and frankly most effective vectors right now are modified viruses, things like adenoviruses or even human influenza virus.

Viruses.

That sounds risky.

Well, they're modified to be safe, hopefully, but they're used because viruses are naturally brilliant at infiltrating cells.

That's their whole biological purpose.

Lipids and plasmids are also being explored as non -viral options.

Our source material mentions figure 5 .1, which gives a good conceptual example for adenosine -demonaise deficiency, AD deficiency.

It shows how they take the therapeutic gene, package it into a viral vector, and then introduce that into the patient's lymphocytes, their immune cells.

The hope is that those modified lymphocytes will then start correctly producing the missing ADA enzyme.

That's the concept.

But direct therapy, as you hinted, has serious limitations.

Because we are often using viruses, there's always a risk, however small, of causing a viral illness or triggering a really severe immune response.

Plus, often the therapeutic effects are only temporary.

The inserted gene might not integrate permanently or might get diluted out as cells divide.

It doesn't always last.

That's a crucial point.

So if direct gene transfer is still largely experimental and potentially temporary, what about the more established, maybe more successful form of gene manipulation?

Ah, that brings us to indirect gene therapy, which is really synonymous with RDNA technology.

This is different.

This involves using those RDNA vectors, often plasmids inserted into bacteria like E.

coli, but it happens in a laboratory setting, not inside the patient.

The goal here is to use these engineered organisms to mass manufacture biological drugs.

And this technology, it's already fundamental to global healthcare.

Right, and the classic pivotal example is insulin.

Precisely.

By inserting the human insulin gene into, say, E.

coli, those bacteria become tiny incredibly efficient insulin factories.

For decades now, this method has produced the vast majority of the world's recombinant human insulin supply.

It really proves that the underlying RDNA technology itself is incredibly robust and scalable.

The challenge remains applying it safely and effectively inside the patient with those viral vectors for direct therapy.

Okay, this is where it gets really interesting, I think, and directly relevant for anyone in clinical practice.

Connecting genetics to how drugs actually work in your specific body, we're talking about pharmacogenomics.

Yes, pharmacogenomics.

That's the big picture.

It's the broad survey of your entire genome to find potentially multiple gene variations that influence how you respond to a drug.

It's a bit broader than pharmacogenetics, which traditionally focused more on single gene variations in drug response.

And they both feed into the same goal.

Exactly.

Both feed into the ultimate goal of personalized medicine.

Truly customizing drug therapy based on your unique molecular and genetic characteristics.

So what's the specific genetic mechanism that makes a drug work perfectly for one person, but maybe fail completely or even cause harm in another?

That mechanism usually involves genetic polymorphisms.

These aren't rare mutations.

They're variations in alleles that occur pretty frequently.

The definition is usually one percent or more the population has this variation.

Clinically, these polymorphisms are critical because they can alter the amount or the function of key biological systems.

Most importantly, they affect the drug metabolizing enzymes like the cytochrome P450 enzymes or CYP enzymes.

And the CYPs.

Heard of those.

Right.

Or polymorphisms can change how drug receptor proteins function, how well a drug can bind and do its job.

So basically, the genotype you inherit determines if you're, say, a poor metabolizer or a rapid metabolizer of certain medications.

That's a major classification, yes.

And knowing which category a patient falls into for a specific drug is absolutely critical for dosing.

Why?

How does it change things?

Well, take warfarin, the blood thinner or Finnytoin, an anti -seizure med.

If you're a rapid metabolizer, your body breaks down the drug very, very quickly.

That might mean you need a significantly higher dose than average just to get any therapeutic effect at all.

OK.

And the opposite?

The opposite is the poor metabolizer.

Their enzymes work slowly, so the drug builds up in their system.

They would need a much lower dose to avoid potentially serious toxicity.

The coding example in the chapter is such a clear illustration of this, isn't it?

Coding itself doesn't do much.

It's a pro -drug.

Exactly.

It only provides pain relief once your body, specifically a CYP enzyme, converts it into active morphine.

So what happens with different metabolizers?

Well, if you're a poor metabolizer of coding, you barely convert any of it to morphine.

So you might take coding and get almost no pain relief.

You'd technically need a higher dose just to get a minimal effect, though usually another drug is chosen.

Right.

But if you're a rapid or even an ultra -rapid metabolizer, you convert that coding to morphine very quickly, potentially leading to high morphine levels.

This puts you at serious risk of over -sedation, respiratory depression, dangerous side effects.

So you'd need a significantly lower dose or, more likely, avoid coding altogether.

Wow.

That really highlights why knowing the patient's genetic profile beforehand is so much better than just trial and error.

Absolutely.

And we already have tools to help figure this out.

Researchers developed DNA microarray technology, things like the AmpliCHIP test.

These can screen a blood sample for thousands of genes simultaneously, essentially mapping an individual's cytochrome enzyme profile before you even write the first prescription.

And the clinical applications are already out there, right?

Table 5 .1 in the text lists several.

Yes, they're becoming more common.

In oncology, for instance, doctors routinely test breast cancer tumors for the Yamtruniu proto -oncogene.

That genetic profile determines if the patient is likely to respond to the targeted therapy trastuzumab, Herceptin.

If you don't have the target, the drug won't work.

Makes sense.

Similarly, identifying the Philadelphia chromosome in certain types of leukemia, like CML, is necessary to know if a patient is a candidate for imatinib bemesylate or Gleevec.

And I think the women's health example is incredibly important, too.

Genotyping for the Factor V Leiden mutation.

Yes.

That identifies women who face a massively increased risk, like sevenfold, sometimes even up to a hundredfold higher risk of blood clots if they use standard oral contraceptives.

Knowing that completely changes the contraceptive counseling process, doesn't it?

It's vital safety information.

It absolutely does, but with this immense power to predict health outcomes, even predispositions, comes really serious regulatory and ethical responsibility.

Definitely.

What are the key safeguards, particularly in Canada?

Well, patient safety is managed through pretty strict oversight.

The Biologics and Genetic Therapies Directorate, or BGTD, which is part of Health Canada,

reviews and approves all clinical trials involving these therapies.

And critically, every hospital or research institution involved must have a research ethics board, an RE.

Their entire job is to protect human subjects involved in research from unethical practices or unnecessary risks.

And the big ethical concern looming over all of this?

The big one is always eugenics.

The idea of intentionally selecting desirable genotypes, perhaps even before birth, it's a very slippery slope.

Because of these deep ethical concerns, Canada currently limits gene therapy research funding primarily to somatic cells that's regular body cells.

Manipulation of germline cells, sperm, or eggs is generally not approved for funding, because any changes made there would be permanent and passed down to all future generations.

That's a line most agree we shouldn't cross right now.

Okay, so this whole emerging field definitely changes things for the general practice nurse, right?

Particularly around assessment.

Nurses might not be sequencing genomes themselves, but they need to be that first line of defense identifying potential genetic risks.

Absolutely crucial role.

So when doing an assessment, it's not just the usual questions anymore.

The nurse needs to get a really thorough personal history, drug history, and perhaps most importantly a detailed family history, ideally looking back at least three generations.

You're listening for those red flags, right?

Like an unusual number of family members with the same disease?

Yes, or diagnosis at a surprisingly young age, or critically reports of unusual or extreme reactions to medications.

Which brings us right back to that codeine case study example mentioned earlier.

When Darla, the patient in the case study, tells the nurse she's allergic to codeine because it just knocks her out, and then mentions her sisters have the exact same reaction.

That's a huge clue.

That is an immediate warning sign.

The nurse shouldn't just chart it as a typical allergy.

It is highly likely that Darla and her sisters are poor metabolizers of codeine due to a specific genetic polymorphism we talked about.

Recognizing that difference, understanding it's likely genetic, not allergic, is absolutely essential for her safety and proper pain management.

And the final piece here, especially with genetic testing and counseling becoming more common, is confidentiality.

Paramount.

Absolutely paramount.

The patient has the absolute right to decide who gets to know their genetic results, whether that's family members, friends, their insurance company, or even other health care providers.

The patient controls that information.

The nurse's ethical obligation is crystal clear.

Ensure strict privacy and vigorously guard against any improper disclosure of that highly sensitive genetic information.

So this deep dive really confirms it.

Genetics isn't some far -off future concept anymore.

It's becoming an integral part of everyday health care right now.

It truly is.

The Human Genome Project absolutely set the stage, and now Pharmacogenomics is delivering on that promise of proactive, customized drug dosing, real personalized medicine.

You, as future or current practitioners, must be prepared to integrate this knowledge, assess for those genetic risks we discuss, and always, always maintain the strictest confidentiality.

Okay, let's wrap up with our final provocative thought for you today.

Consider this the fact that indirect gene therapy, that RDNA technology, already produces the majority of the world's insulin supply.

That just shows how fundamental and established this technology already is.

So what other vital body proteins, maybe critical enzymes that people lack, essential hormones or maybe growth factors, will we soon be able to manufacture or modify using these same proven RDNA principles?

How might that transform the treatment of countless chronic complex diseases?

Something to think about.

Thank you so much for joining us for this deep dive.

We really hope you feel thoroughly informed and ready to engage the future of health care.

From the whole Last Minute Lecture Team, thanks for listening.